SCHEMBL4847997

SCHEMBL4847997

COc1cc(B2OC(C)(C)C(C)(C)O2)ccc1-c1nnc(C)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.43
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
BRD4 O60885 1/20 0.38
GUSB P08236 6/20 0.37
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
LRRK2 Q5S007 1/20 0.35
SNCA P37840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850342 0.80 ALDH1A1 (0.45) CSF1RALDH1A1LMNAMAPTHPGD
SCHEMBL12918690 0.76 GUSB (0.49) ALDH1A1LMNAKDM4EMAPTHPGD
SCHEMBL21217997 0.76 CSF1R (0.40) CSF1RALDH1A1LMNAKDM4EMAPT
SCHEMBL1458494 0.75 LPL (0.53) KDM4EHPGDSMN1; SMN2SNCALPL
SCHEMBL23199590 0.75 BRD4 (0.33) CSF1RBRD4LPLLIPG
SCHEMBL30197526 0.74 CSF1R (0.49) CSF1RSNCALPLLIPGCA1
SCHEMBL6921637 0.74 CSF1R (0.49) CSF1RSNCALPLLIPGCA1
SCHEMBL1877988 0.74 CSF1R (0.48) CSF1RSNCALPLLIPGCA1
SCHEMBL25203373 0.74 CSF1R (0.48) CSF1RSNCALPLLIPGCA1
SCHEMBL4281887 0.74 GUSB (0.60) ALDH1A1LMNABRD4GUSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CSF1R 3275/4885ALDH1A1 3257/4885LMNA 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.